You're watching...
Actavis CEO Paul Bisaro on the latest trends in pharmaceuticals and the impact of the health-care law.
Also in this playlist...
Auto-advance: ON
Auto-advance
This transcript is automatically generated
Very much.
As many big pharmaceutical companies are battling the so called patent cliff one drugmaker is cruising through with its earnings to show for it take a look at activists.
The newly merged company.
Activists and Watson Pharmaceuticals now called activist beat expectations on both the top and bottom line -- stocked up about 200%.
Since 2008.
Paul Lazaro is activist CEO and president joining me -- Fox Business exclusive us very good -- Yes very nice numbers what really drove at this time -- we should explain to people that you really cover both ends of the spectrum generics and specialty trucks.
Well we actually had a great year we we were up on the generic side are activists pharma division we're also up on our brand side two with revenues being up there as well and and we look for this balanced business model really is to go forward.
Opportunities is of course for us it is was also going global.
This -- we're now -- 62 markets around the world great opportunities in those markets what is your best selling generic round.
Well our best selling generic drug is is probably concern it's it's a drug for at EDT.
And now we've been marketing for about a year we've done quite well veteran you've got to Lipitor generic -- -- we have a Lipitor generic on that product is not quite as good anymore because there's a lot of competition in the market so it's fallen off.
Last year it was a big drug this year hasn't been to what you have any Blockbuster drugs.
I'm -- -- by the way the definition is -- billion or more in -- you know criteria but no not quite there we hope to get -- but not yet -- -- -- imagining -- the doberman Pincher here in just a more mid -- dog at this point but hey why not you can believe in that because.
You guys are again at looking at both sides at this.
But the bio similar part of -- I wanted to teach people a little bit about this -- similar.
It of those are drugs that actually are derived from living organisms correct that's right with a new way of the future.
Right we call the large molecules and in them about well probably did that expectations are in 2016.
But all the top ten drugs will be bio biologic products how are -- sure that well you can just see the numbers.
-- -- the numbers from Amgen and and what it has -- would have -- -- Everything worse from -- rheumatology to oncology.
Monoclonal antibodies all of these things are targeted drugs and they do a fantastic job.
What we're working on is the next wave we call by a similar -- -- products that are similar to those -- -- sold at a lower cost highly effective.
Safe but so little lower cost to help reduce health care costs not just in the US.
Course but around the world health care costs obviously our topic of conversation today a lot of the HMO's are dropping because they're worried that.
Medicare rates will go down and they're very concerned to try to protect us what somebody stepped on their air hose but hasn't stepped on your air -- how would this affect you at all.
Well it's really won't affect -- all that much I mean Medicare Medicaid is part of our overall business model we do you have obviously sales to to those sectors.
But overall that shouldn't really affect us too much we will probably be actually benefited by the universal health programs.
As more not prescriptions are filled in the US.
Tom but again I think the bigger driver for us as a company.
Is -- the global need to drive down health care cost generic medicines do that they drive down health care cost and all the markets finished.
Wrapped around the world but you must spend a lot of time in the courtroom and I'm talking -- in the collective view of -- because when -- General Counsel thank goodness your lawyer of -- -- Pharmaceuticals Bakken.
Back in the day but.
Because their -- lawsuits from you know people -- -- protect the patent that they had in the new file appeals and then you go back and forth how how much of your intellectual.
Band with this spent on this.
Well we do have a lot of lawyers on staff and we spent a lot of time looking impact a lot of -- -- small law firm might not.
How about I fed -- bits we spent a lot of time looking at patents and non and looking at those that we think are arch eligible and if we successfully challenge of patent.
We get a 180 days of generic exclusivity so there's an upside -- -- us as well wolf shore 180 days with a lot of patience enough time in new refills.
The patent cliff and we just put our version of it up there how do you take advantage of that as many different drugs.
Patents expire.
Well it's it's true across the world right patent cliff does is hitting everywhere in the US is sitting in Europe -- hardest hit gets hit -- -- so those are opportunities for us of course is where as we can bring generic medicines to markets.
When those patents expire or if we can defeat depends remembering him earlier.
So it's really just an upside for us let's talk about your European business last year -- you were jumping about 20% year over year in your European revenues -- -- -- do that.
At a time where.
That area's very weak at least certain parts of -- the club so called club met nations do you expect that.
Nice jump this year or will moderate as well you know it coordinate better the world's person that's a big spread of the country some countries were -- some countries are down but for us we spent a lot of time and money on organic growth we have a very strong -- program.
And really what it was about -- launching new products.
And that will be the trigger that'll be true for next from this year 2013 and fourteen as we finish up your your best drug best hope drug at this point figure excited about.
I'm excited about a lot of drugs than the big drug for us -- will be launching later this this summer is Latin term it's a patch for a pain.
Look for that in September okay no pills to swallow no injections.
The stock is up 45%.
Your for you're depressed earnings ratio of ten that would be considered inexpensive.
-- Paul good to see if thank you have Paul -- RO activist CEO and president in a Fox Business exclusive closing bell ringing.
